Ships within 24 hours on business days · +10% with Bank Pay

Dihexa Capsules

Shop

Dihexa Capsules · Research brief

Dihexa Mechanism of Action: How Does Dihexa Work?

44 WORDS

Short answer

The Dihexa mechanism of action, as the published literature describes it, is indirect rather than direct: the molecule is not characterized as switching on a classical cell-surface receptor by itself, but as working through hepatocyte growth factor (HGF) and its receptor tyrosine kinase, c-Met.

The Dihexa mechanism of action, as the published literature describes it, is indirect rather than direct: the molecule is not characterized as switching on a classical cell-surface receptor by itself, but as working through hepatocyte growth factor (HGF) and its receptor tyrosine kinase, c-Met. Research on this angiotensin IV derived compound suggests that it associates with HGF and increases the ability of that growth factor to activate c-Met, which in turn engages the kinase cascades associated with dendritic spine formation and synapse assembly in neural tissue. Where c-Met signaling is blocked or where HGF is absent from the system, the reported activity is described as falling away, which is why the compound is usually classed in the literature as an HGF potentiator or HGF mimetic rather than a direct receptor agonist. Everything below is preclinical and laboratory evidence; Dihexa is a research-use-only compound, not a human therapeutic.

What is Dihexa and where did the molecule come from?

Dihexa is a small peptide-derived molecule built on the angiotensin IV scaffold. Angiotensin IV is a short fragment of the renin-angiotensin system, and a body of rodent work beginning in the 1990s reported that this fragment and its relatives influenced hippocampal function and performance in learning tasks. The practical obstacle with angiotensin IV itself is that it is cleaved quickly by aminopeptidases and does not distribute well into the central nervous system, so the activity observed when it was applied directly to brain tissue was difficult to reproduce by other means.

Medicinal chemistry programs responded by truncating the parent peptide and capping its ends. Dihexa, formally described as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, is the best known product of that effort: a tyrosine and an isoleucine flanked by a hexanoic acid group and an aminohexanoic amide group. Those lipophilic caps are what distinguish it from the parent fragment, because they both block aminopeptidase attack and raise lipophilicity, two properties the literature links to metabolic stability and membrane permeability.

The compound has never been an approved medicine in any jurisdiction, and the available evidence base is preclinical. For laboratory procurement, the relevant checks are identity checks: matching the CAS number and molecular identity stated by the supplier against the certificate of analysis for the specific lot. Real Peptides supplies Dihexa as a research-use-only catalog compound and publishes independent third-party certificates of analysis for every batch at /coas/, which is the document a laboratory uses to confirm that the material in hand is the molecule described in the literature.

How does Dihexa work at the molecular level?

At the molecular level, research suggests Dihexa acts as a positive modulator of hepatocyte growth factor rather than as a ligand that occupies a receptor pocket on its own. The model described in the literature runs in three steps. First, the small molecule associates with HGF, the natural protein ligand. Second, that association is reported to favor the clustered or multimeric form of HGF that is most effective at engaging c-Met. Third, the better-engaged c-Met receptor undergoes dimerization and autophosphorylation on its intracellular tyrosine residues, which creates docking sites for adaptor proteins and starts the downstream cascade.

This is a different kind of pharmacology from a small molecule that binds a G protein-coupled receptor. In the HGF potentiation model, the compound has no activity of its own in a system with no growth factor present; it amplifies a signal that is already there. That framing explains several features of the reported data set, including why the literature describes effects at very low concentrations and why the effect is said to disappear when c-Met is inhibited or silenced.

The limits here matter. The precise binding site on HGF, the binding affinity, and the structural basis of the interaction are not resolved in the accessible literature, and no published crystal or cryo-EM structure of the complex is described. The mechanism is therefore best stated as a functional hypothesis supported by pharmacological dependence experiments rather than as a structurally confirmed receptor interaction. Readers should treat descriptions of exact molecular contacts with caution, because the literature does not specify them.

Does Dihexa bind a receptor directly, or does it act through HGF?

The weight of the published work points to action through HGF rather than direct receptor binding, which is the key point for anyone searching on Dihexa receptor binding. The evidence cited for this is pharmacological dependence: the reported synaptogenic and procognitive effects of angiotensin IV derived analogs are described as requiring an intact HGF/c-Met system, so that interfering with c-Met removes the effect. If the molecule were a direct c-Met agonist occupying the orthosteric site, blocking HGF would not be expected to abolish activity in the same way.

That said, the distinction between a growth-factor binder, an allosteric receptor modulator, and a true mimetic is not fully settled. Different reports and reviews have used the terms HGF mimetic, HGF potentiator, and small-molecule angiotensin IV analog for the same compound, and these labels carry different mechanistic commitments. A mimetic would be expected to activate c-Met without HGF present; a potentiator would not. The literature as it stands leans toward potentiation, but it does not close the question with binding constants or structural data.

For a researcher designing an experiment, the practical implication is that the HGF content of the model system is a variable, not a constant. Serum-containing culture media, primary neuronal preparations, and intact brain tissue all differ in available growth factor, and the same concentration of compound may behave differently across them. Control arms that manipulate HGF availability or c-Met activity are what give a mechanism experiment its interpretive power here.

What is the HGF/c-Met system and why does it matter in neural tissue?

Hepatocyte growth factor is a multidomain protein first characterized for its role in liver regeneration, and c-Met is the receptor tyrosine kinase it activates. The identification of the c-met proto-oncogene product as the HGF receptor was reported in Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product, Science, 1991, and that pairing anchored decades of work on growth, motility, and morphogenesis. A later overview, The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine, Proceedings of the Japan Academy, 2010, describes how the same ligand-receptor pair is involved in tissue repair across multiple organ systems.

The system is not confined to the liver. MET signalling: principles and functions in development, organ regeneration and cancer, Nature Reviews Molecular Cell Biology, 2010 describes c-Met activity in development, epithelial morphogenesis, and regeneration, and also in oncogenic signaling when the pathway is constitutively active. Both HGF and c-Met are expressed in the central nervous system, where research has linked the pathway to neurite outgrowth, neuronal survival, and the structural plasticity of dendrites.

That neural expression is the bridge to Dihexa. If a small molecule can raise the gain on HGF signaling in brain tissue, the predicted consequences are the ones reported in the angiotensin IV analog literature: more dendritic spines, more functional synaptic connections, and changes in hippocampus-dependent task performance in rodents. The limits of this inference are worth stating plainly. Pathway involvement in plasticity does not establish that a given compound produces a durable or beneficial change in an intact organism, and the cancer biology of c-Met is a standing reason that researchers treat chronic pathway amplification as a question rather than an assumption.

What downstream signaling pathways follow c-Met activation?

Once c-Met dimerizes and autophosphorylates, it recruits adaptor and scaffold proteins to its multifunctional docking site, and the signal branches. An overview of the c-MET signaling pathway, Therapeutic Advances in Medical Oncology, 2011 describes the principal branches: the Ras/MAPK cascade, the PI3K/Akt axis, phospholipase C gamma, STAT3, and signaling through the Gab1 scaffold, with Src family kinases and focal adhesion components participating in the cytoskeletal arm.

Each branch maps onto a plausible piece of the reported phenotype. Ras/MAPK signaling converges on transcription factors including CREB, which regulates genes associated with synaptic plasticity. PI3K/Akt signaling supports cell survival and local protein synthesis in dendrites. The cytoskeletal arm, acting through Rho family GTPases and actin regulators, is the most direct route to a change in spine number or spine morphology, because spine formation is fundamentally an actin remodeling event.

The literature on Dihexa itself describes changes consistent with activation of these branches, including increased c-Met phosphorylation and downstream kinase activity in neural preparations. What it does not provide is a complete, quantified signaling map specific to the compound across cell types and time points. Pathway-level claims should therefore be read as plausible mechanism rather than measured fact for any particular model.

There is also a selectivity question. These same cascades sit downstream of many receptor tyrosine kinases, so observing MAPK or Akt phosphorylation after exposure does not by itself prove the signal entered through c-Met. Receptor-level controls, not pathway-level readouts, are what distinguish the proposed mechanism from a general growth-factor effect.

Does Dihexa increase BDNF?

The honest answer is that the mechanism described in the Dihexa literature is an HGF/c-Met mechanism, not a BDNF mechanism, and the available evidence does not establish BDNF induction as the compound's primary mode of action. Brain-derived neurotrophic factor acts through its own receptor, TrkB, and the neurotrophin system is described in Neurotrophins: roles in neuronal development and function, Annual Review of Neuroscience, 2001 as a distinct ligand-receptor family with its own regulation and its own developmental and plasticity roles.

Where confusion arises is that TrkB and c-Met are both receptor tyrosine kinases, and both feed the same downstream machinery: Ras/MAPK, PI3K/Akt, PLC gamma, and CREB-dependent transcription. A compound that raises c-Met signaling will therefore produce intracellular events that look, at the level of phosphorylated kinases, similar to what BDNF produces. That convergence is a reason to be careful with readouts, because a change in phospho-CREB or phospho-Akt does not identify which receptor started the cascade.

It is also biologically plausible that activity-dependent or plasticity-associated signaling raises neurotrophin expression as a secondary consequence, and researchers sometimes measure BDNF transcript or protein alongside other markers for that reason. But a secondary or correlated change is not a mechanism. The literature accessible on this compound does not provide a clear, replicated demonstration that it raises BDNF levels as the driver of its effects, and no specific figure for such a change can be stated here without inventing one.

For laboratories interested in the question, the design that answers it is comparative: measure neurotrophin expression with and without c-Met inhibition, and separate direct TrkB engagement from downstream convergence using receptor-specific blockade.

What does the synaptogenesis literature report about angiotensin IV derived analogs?

The research line that produced Dihexa was built around synaptogenesis as the measured endpoint. Reports on angiotensin IV derived peptides describe increases in dendritic spine density and in the number of functional synaptic contacts in hippocampal neuron preparations, together with electrophysiological changes consistent with more connections rather than a change in the properties of existing ones. The same research line reports performance changes in rodent spatial learning tasks in models where cholinergic signaling or hippocampal tissue has been compromised.

The mechanistic claim attached to these observations is that the spine and synapse changes depend on the HGF/c-Met system, because interfering with that system is described as preventing them. That dependence experiment is the strongest single piece of evidence behind the whole mechanism story, and it is why this page frames the compound as a growth-factor potentiator.

The limits are substantial and should be stated. Spine counting is an imaging-intensive measurement with real inter-laboratory variability. Rodent cognitive tasks are sensitive to handling, housing, and strain. Most of the primary work comes from a comparatively small research field rather than from many independent groups, and independent replication across laboratories is thin. Published human clinical evidence is not established, so none of the rodent or culture findings can be carried over to human physiology.

Researchers reading this literature should also note the difference between an acute structural change and a durable one. Reports of persistence after exposure ends are interesting precisely because they are unusual, and claims of that kind need replication before they become settled facts.

How does Dihexa relate to the AT4 receptor and insulin-regulated aminopeptidase?

Because Dihexa descends from angiotensin IV, the AT4 binding site is part of its background. Angiotensin IV binds a site historically called the AT4 receptor, and Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase, Journal of Biological Chemistry, 2001 reported that this site corresponds to insulin-regulated aminopeptidase, or IRAP, a transmembrane zinc metallopeptidase rather than a classical signaling receptor.

That identification created two competing explanations for the cognitive effects of angiotensin IV in rodents. One is that the peptide inhibits IRAP enzymatic activity, slowing the breakdown of endogenous peptides such as vasopressin and oxytocin that have their own effects on hippocampal function. The other is that the peptide or its analogs act through the growth factor pathway described above. The literature on Dihexa specifically leans toward the HGF/c-Met explanation, since its reported effects are described as c-Met dependent, but the IRAP hypothesis has not been eliminated from the broader angiotensin IV field.

It is also possible that both hold at once for different molecules in the series. Structural modification changed the series substantially, and an analog with large lipophilic caps need not retain the binding behavior of the parent hexapeptide at a peptidase active site. The literature does not provide a clean comparative binding panel across IRAP, c-Met, and HGF for this compound, so the relative contribution of each interaction remains an open experimental question rather than a settled allocation.

What is the mechanism of drug action?

Mechanism of drug action is the description of the specific molecular interaction through which a compound produces its effect: which target it engages, what it does to that target, and what cascade follows. A complete mechanism statement names a molecular target, a type of interaction, and a measurable downstream consequence. Saying that a compound improves a function is an effect statement; saying that it binds a particular receptor subtype and increases its phosphorylation is a mechanism statement.

Mechanisms are described at different levels of resolution, and the level matters. At the molecular level, the statement is about binding: agonist, antagonist, inverse agonist, allosteric modulator, enzyme inhibitor, channel blocker, or, as in this case, a modulator of a natural ligand. At the cellular level, the statement is about pathway activation and the proteins recruited. At the tissue or system level, the statement is about the functional change produced, such as altered synapse number.

Applying this to the compound on this page: the molecular-level mechanism is described as association with hepatocyte growth factor and potentiation of its action; the cellular-level mechanism is c-Met autophosphorylation and activation of MAPK, PI3K/Akt, and related cascades; and the tissue-level consequence reported in rodent and culture models is increased dendritic spine and synapse formation. Each level rests on different evidence, and the molecular level is the least firmly established of the three, which is exactly the kind of gap a mechanism statement should make visible rather than hide.

What is mechanism of action in pharmacology?

In pharmacology, mechanism of action is the formal answer to how a compound produces its biological effect, stated in terms of the target it engages and the biochemical consequence of that engagement. It is one of the core descriptors applied to any compound, alongside its chemical identity, its disposition in the body, and its measured effects. Regulatory and academic writing both expect a mechanism statement to be specific: naming a target family is a weaker claim than naming a receptor subtype, and naming a subtype is weaker than specifying the binding mode.

Pharmacology distinguishes mechanism of action from mode of action. Mode of action is the broader functional description, for example promoting synapse formation, while mechanism of action is the molecular route to that description, for example amplifying growth factor signaling at a receptor tyrosine kinase. Many compounds in common use have a well-characterized mode of action and an only partially characterized mechanism, which is a normal state of knowledge rather than a failure.

Mechanism claims are built from a standard toolkit: binding assays that measure affinity, functional assays that measure activation or inhibition, knockdown or knockout models that remove the proposed target, and selective inhibitors that block the proposed pathway. The strongest mechanism statements are supported by several of these in combination. For Dihexa, the dependence-on-c-Met evidence is present; the direct binding characterization is not described in the accessible literature, which is why the mechanism is usually presented with hedged language.

Is pharmacodynamics the same as mechanism of action?

No, although the two overlap. Pharmacodynamics is the study of what a compound does to the body, covering the full relationship between the amount present at the site of action and the magnitude of the resulting effect. Mechanism of action is one component of pharmacodynamics: the molecular explanation of how the effect arises. Pharmacodynamics also includes concentration-effect relationships, efficacy and potency measures, receptor occupancy, tolerance and sensitization, and the time course of effect.

Put differently, mechanism of action answers which target and what interaction, while pharmacodynamics answers how much effect follows from how much compound, and how that effect changes over time. Two compounds can share a mechanism and differ sharply in pharmacodynamics, for example if one has far higher affinity or a much longer receptor residence time. Conversely, two compounds with different mechanisms can produce similar pharmacodynamic curves for a chosen endpoint.

For a growth factor potentiator, the pharmacodynamic picture is unusual, because the effect ceiling depends on how much natural ligand is available. In a system with abundant HGF, a potentiator may produce a large signal; in a depleted system it may produce almost none. That ligand dependence is a pharmacodynamic property that follows directly from the proposed mechanism, and the published literature does not provide the systematic concentration-response mapping across model systems that would characterize it fully.

Is mechanism of action the same as pharmacokinetics?

No. Mechanism of action describes what the compound does to its target. Pharmacokinetics describes what the biological system does to the compound: absorption, distribution, metabolism, and elimination. They are complementary and independent descriptions, and a compound can have an elegant mechanism and useless pharmacokinetics, or excellent pharmacokinetics and no useful mechanism.

The shorthand used in teaching is that pharmacokinetics is what the body does to the drug, pharmacodynamics is what the drug does to the body, and mechanism of action is the molecular detail inside pharmacodynamics. All three are needed to interpret an experiment. A negative result in an intact animal can mean the mechanism is wrong, or it can mean the compound never reached the tissue where the target sits, and only pharmacokinetic measurement distinguishes those two explanations.

This distinction is the whole reason Dihexa exists as a molecule. The parent angiotensin IV fragment had an interesting mechanism story but poor pharmacokinetic behavior, being quickly degraded and poorly distributed into the brain. The structural modifications that produced the analog were aimed at the pharmacokinetic side of the problem, not the mechanistic side. Any evaluation of the compound in a whole-animal model is therefore testing both propositions at once, which is one reason culture and slice work remain central to the mechanism literature.

What is known about the metabolic stability and brain penetration of Dihexa?

The literature describes the compound as having been designed for metabolic stability and central nervous system access, and those design goals are the stated reason for its structure. The hexanoic acid and aminohexanoic amide caps remove the free termini that aminopeptidases attack, and they raise lipophilicity, which is the property most often associated with passive partitioning across the blood-brain barrier for small molecules.

Reports in the angiotensin IV analog literature describe the resulting molecule as reaching brain tissue and as being more resistant to degradation than its parent, which is the basis for its use in whole-animal experiments. Specific stability half-lives, brain-to-plasma ratios, and distribution figures are not reproduced here because the accessible literature does not provide values that can be stated with a verifiable citation, and a precise invented number would be worse than none.

Two caveats follow. First, lipophilic modification affects more than permeability: it changes plasma protein binding, non-specific tissue partitioning, and solubility behavior in aqueous laboratory media, all of which complicate the comparison between a culture concentration and a whole-animal exposure. Second, stability in one species or matrix does not predict stability in another, and the published data set is narrow.

For laboratory work, solubility and handling behavior are properties to confirm against the certificate of analysis and the supplier's stated storage conditions rather than to assume from structure. Real Peptides publishes lot-specific documentation at /coas/ for exactly this reason.

What experimental models have been used, and what are their limits?

The mechanism evidence sits in three model classes. Cell and primary culture work, including dissociated hippocampal neurons, provides the spine and synapse counts and the receptor-level dependence experiments. Hippocampal slice preparations provide electrophysiological readouts of connectivity. Whole-animal rodent work provides behavioral endpoints in spatial learning tasks, frequently in models where cholinergic function has been disrupted or hippocampal tissue damaged.

Each class carries characteristic limits. Culture systems lack the vascular, glial, and network context of intact tissue, and growth factor availability in culture medium is an artificial variable. Slice preparations preserve local circuitry but are acute and metabolically stressed. Rodent behavioral models of cognitive impairment reproduce selected features of human conditions and are not the conditions themselves; performance changes in a maze are not clinical outcomes.

Across all three, the field-level limit is concentration of evidence. Much of the primary work originates from a narrow research base rather than from broad independent replication, and the reported effects have not been established in published human clinical research. For that reason, every mechanistic statement on this page is attributed and hedged, and none of it should be read as describing what the compound does in people.

The constructive reading for a laboratory is that the mechanism offers testable predictions: HGF dependence, c-Met phosphorylation, cytoskeletal remodeling, and loss of effect under receptor blockade. Those predictions can be tested directly in well-controlled systems, and that is where the next informative data are likely to come from.

What remains unresolved about Dihexa receptor binding?

Several questions are genuinely open. The first is the binding interaction itself: the literature does not supply a measured affinity, a defined binding site on HGF, or a structural model of the complex, so the potentiation mechanism rests on functional inference. The second is selectivity. Whether the molecule interacts with IRAP, with other peptidases, or with other receptor tyrosine kinase systems at comparable concentrations has not been mapped in a published comparative panel.

The third is the biology of sustained pathway amplification. Because c-Met is an oncogene product and its constitutive activation is central to several tumor biologies, as described in the Nature Reviews Molecular Cell Biology overview cited above, prolonged amplification of this pathway is a safety question that preclinical literature has not resolved. That is a reason for caution in experimental design and a reason the compound remains restricted to research settings.

The fourth is translation. Rodent synaptogenesis and maze performance are informative endpoints in the models where they were measured, and no published human clinical evidence establishes corresponding effects. The fifth is reproducibility: independent replication of the central dependence experiments by unaffiliated laboratories would strengthen the mechanism considerably, and that work is not widely represented in the published record.

Stating these gaps is not a criticism of the research line. It is the accurate state of a preclinical mechanism that has a coherent hypothesis, supportive functional data, and incomplete molecular characterization.

How do laboratories source and verify Dihexa for research use?

Sourcing for mechanism work begins with identity and documentation rather than with marketing claims. A laboratory confirms the compound name and CAS number against the certificate of analysis for the specific lot received, checks that the analytical methods reported on that document match the molecule, and records the lot identifier alongside the experimental data so that results remain traceable. Real Peptides supplies Dihexa as a research-use-only catalog compound and publishes independent third-party certificates of analysis for every batch at /coas/.

Real Peptides does not provide preparation, handling, or use guidance for any catalog compound, because these materials are sold for laboratory research only.

Background on the compound, its literature, and its catalog listing is available on the Dihexa compound page and the Dihexa product listing, with the wider catalog at /shop/ and shipping and location details at /location/.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.

References

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

Research suggests it works indirectly, by associating with hepatocyte growth factor and increasing that growth factor's ability to activate the c-Met receptor tyrosine kinase. Activated c-Met then drives MAPK, PI3K/Akt and cytoskeletal signaling linked to dendritic spine formation. Reported effects fall away when c-Met signaling is blocked, supporting a potentiator rather than direct agonist model.
The literature does not establish BDNF induction as this compound's mechanism. The described mechanism runs through hepatocyte growth factor and c-Met, a separate receptor tyrosine kinase system. Because c-Met and the BDNF receptor TrkB share downstream cascades, phospho-kinase readouts can look similar without BDNF being the driver, so receptor-level controls are needed.
Mechanism of drug action is the description of the specific molecular interaction through which a compound produces its effect: the target engaged, the nature of that engagement, and the cascade that follows. It is stated at molecular, cellular and tissue levels, and a complete statement names a target rather than only describing an observed outcome.
In pharmacology, mechanism of action is the formal molecular answer to how a compound produces its biological effect, named by target and interaction type: agonist, antagonist, allosteric modulator, enzyme inhibitor or growth factor potentiator. It is distinguished from mode of action, which describes the broader functional consequence rather than the molecular route to it.
No. Mechanism of action is one component of pharmacodynamics. Pharmacodynamics covers everything a compound does to the biological system, including concentration-effect relationships, potency, efficacy, receptor occupancy and time course. Mechanism of action is narrower, answering only which target is engaged and how that engagement produces the measured effect.
No. Pharmacokinetics describes what the biological system does to a compound, covering absorption, distribution, metabolism and elimination. Mechanism of action describes what the compound does to its molecular target. Both are needed to interpret an experiment, because a negative whole-animal result may reflect a wrong mechanism or simply poor tissue exposure.
The accessible literature does not describe direct orthosteric binding to c-Met. The prevailing model is association with hepatocyte growth factor itself, which then engages c-Met more effectively. Binding affinity, the exact site on the growth factor and structural data for the interaction are not specified, so the mechanism rests on functional dependence experiments.
No. Real Peptides supplies research-use-only compounds and does not provide preparation, handling or use guidance. What can be explained is the concentration framework: mass divided by solvent volume gives milligrams per millilitre, and assay work is expressed in micrograms per assay or molar concentration. Lot certificates of analysis are published at /coas/.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now